DE3780618T2 - Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses. - Google Patents

Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.

Info

Publication number
DE3780618T2
DE3780618T2 DE8787307054T DE3780618T DE3780618T2 DE 3780618 T2 DE3780618 T2 DE 3780618T2 DE 8787307054 T DE8787307054 T DE 8787307054T DE 3780618 T DE3780618 T DE 3780618T DE 3780618 T2 DE3780618 T2 DE 3780618T2
Authority
DE
Germany
Prior art keywords
buspiron
time memory
improve short
short
improve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787307054T
Other languages
English (en)
Other versions
DE3780618D1 (de
Inventor
Marc T Alderdice
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of DE3780618D1 publication Critical patent/DE3780618D1/de
Application granted granted Critical
Publication of DE3780618T2 publication Critical patent/DE3780618T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DE8787307054T 1986-10-07 1987-08-10 Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses. Expired - Fee Related DE3780618T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/916,661 US4687772A (en) 1986-10-07 1986-10-07 Method for improvement of short term memory

Publications (2)

Publication Number Publication Date
DE3780618D1 DE3780618D1 (de) 1992-08-27
DE3780618T2 true DE3780618T2 (de) 1993-01-21

Family

ID=25437646

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787307054T Expired - Fee Related DE3780618T2 (de) 1986-10-07 1987-08-10 Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.

Country Status (5)

Country Link
US (1) US4687772A (de)
EP (2) EP0276536B1 (de)
JP (1) JPS63101324A (de)
AT (1) ATE78399T1 (de)
DE (1) DE3780618T2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3736974A1 (de) * 1987-10-31 1989-05-11 Troponwerke Gmbh & Co Kg Verwendung von 2-pyrimidinyl-1-piperazin-derivaten
US5468749A (en) * 1988-08-30 1995-11-21 Gawin; Frank H. Method for treatment of substance addiction
GB8826308D0 (en) * 1988-11-10 1988-12-14 Nat Res Dev Memory-enhancing compositions containing dioxopiperidine derivatives
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5824680A (en) * 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
EP1904066B1 (de) 2005-07-06 2018-05-23 Sunovion Pharmaceuticals Inc. KOMBINATIONEN VON ESZOPICLON UND TRANS-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALINAMIN ZUR BEHANDLUNG DER MENOPAUSE, Perimenopause UND VON KOGNITIVEN STÖRUNGEN
GT200600416A (es) * 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
GT200600414A (es) * 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
PE20070523A1 (es) * 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
EP2013835B1 (de) * 2006-03-31 2015-11-04 Sunovion Pharmaceuticals Inc. Herstellung von chiralen amiden und aminen
WO2010132521A1 (en) * 2009-05-13 2010-11-18 Sepracor Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof
CN102918031A (zh) 2010-05-28 2013-02-06 通用电气健康护理有限公司 放射标记的化合物及其方法
CN105193809B (zh) 2010-10-15 2019-07-16 康特拉医药公司 用于治疗运动障碍的血清素受体激动剂组合物
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
US10561618B2 (en) 2012-04-18 2020-02-18 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
EP3481385A1 (de) 2016-07-11 2019-05-15 Contera Pharma APS System zur pulsierenden medikamentenabgabe für die behandlung von morgendlicher akinesie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders

Also Published As

Publication number Publication date
DE3780618D1 (de) 1992-08-27
JPH045648B2 (de) 1992-02-03
EP0276536B1 (de) 1992-07-22
EP0276536A2 (de) 1988-08-03
ATE78399T1 (de) 1992-08-15
EP0276543A3 (de) 1989-08-30
EP0276543A2 (de) 1988-08-03
EP0276536A3 (en) 1989-08-30
JPS63101324A (ja) 1988-05-06
US4687772A (en) 1987-08-18

Similar Documents

Publication Publication Date Title
DE3780618T2 (de) Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.
DE3788739T2 (de) Oxadiazole zur Verwendung in der Behandlung von Dementia Senilis.
FI863160A0 (fi) Anlaeggning foer fiskodling i havsvatten.
DE3889245T2 (de) Integrierter und kontrollierter Leistungs-MOSFET.
DE3789530T2 (de) Klonierung und Expression des sauren Fibroblastenwachstumsfaktors.
DE3873945T2 (de) Verwendung von polyglutaminsaeure in nahrungsmitteln.
MC1884A1 (fr) Variants de l'hirudine,leur utilisation et leur preparation
DE3685258D1 (de) Verwendung von pflanzenprotoplasten.
ATE39694T1 (de) (pyrrol-1-yl)-phenyl-dihydropyridazinone, ihre herstellung und verwendung.
DE3882255D1 (de) Ein-schritt-enzymatische konversion von cephalosporin c und seiner derivate in 7-aminocephalosporinsaeure und derivate.
ATE116854T1 (de) Verwendung von buspiron in schlaf-apnoe.
ATE51229T1 (de) Oxa- und thiadiazolylderivate und ihre verwendung.
DE3781667T2 (de) Verwendung von 24,25-dihydroxycholecalciferol zur verhuetung des knochenalterns.
NO891718D0 (no) Ekspresjon av humant interleukin-2 i metylotrofe gjaersorter.
IT1217352B (it) Palizzata in calcestruzzo nonche'procedimento e dispositivo per laproduzione della stessa.
DE3863093D1 (de) Sulfosuccinamidsaeuren von polyoxypropylendiaminen und ihre verwendung als emulgatoren.
FI871737A0 (fi) Kraftanlaeggning med foerbraenning i en fluidiserad baedd.
DE58904702D1 (de) Beta-phenoxyethylamine und deren verwendung zur herstellung von farbstoffen.
ATE74755T1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE3481403D1 (de) Verwendung von "nafazatrom".
ATE77952T1 (de) Verwendung von 1,4-dihydropyridinderivaten.
ATE100100T1 (de) Oxadiazole zur verwendung in der behandlung von dementia senilis.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ATE65398T1 (de) Verwendung von oxirancarbonsaeuren zur behandlung der hyperlipaemie.
ATE79724T1 (de) Verwendung von polyglutaminsaeure in nahrungsmitteln.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee